Information:
Fel:
ID
34149
Beskrivning
PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00816582
Länk
https://clinicaltrials.gov/show/NCT00816582
Nyckelord
Versioner (1)
- 2019-01-14 2019-01-14 -
Rättsinnehavare
GSK group of companies
Uppladdad den
14 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT00816582
Eligibility Breast Cancer NCT00816582
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00816582
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
post-menopausal (≥ 60 years old, or age ≥ 45 years with amenorrhea for > 12 months or follicle stimulating hormone and estrogen levels within post-menopausal range, or prior bilateral oophorectomy)
boolean
ID.2
Item
hormone receptor positive (er and/or pgr) disease as determined locally
boolean
ID.3
Item
who performance status 0-2
boolean
ID.4
Item
life expectancy of ≥ 3 months
boolean
ID.5
Item
the presence of at least one measurable or evaluable (non-measurable) lesion
boolean
ID.6
Item
informed consent prior to any study procedures
boolean
ID.7
Item
life threatening metastatic visceral disease
boolean
ID.8
Item
brain or leptomeningeal metastases
boolean
ID.9
Item
prior exposure to fulvestrant
boolean
ID.10
Item
history of bleeding diathesis or need for long term anti-coagulation
boolean